NCT03539536 2025-11-05Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerAbbViePhase 2 Active not recruiting270 enrolled 1 FDA
NCT05513703 2025-10-24A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)AbbViePhase 2 Terminated9 enrolled 13 charts